Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07140757 · ClinicalTrials.gov registry record
Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers
A clinical trial of Papillary Thyroid Cancer and Radiofrequency Ablation, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT07140757 is a study of Papillary Thyroid Cancer and Radiofrequency Ablation that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants, below the 438-participant average among 6 other Papillary Thyroid Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07140757, a study of Papillary Thyroid Cancer and Radiofrequency Ablation, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
To track the outcomes of patients who have been treated with RFA and its long-term effectiveness, and to learn more about the quality of life of patients who have received RFA in this study.
Conditions Studied
Interventions
- OTHER Questionnaire
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-08-18 |
| Est. Completion | 2030-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07140757
The ClinicalTrials.gov registry entry for NCT07140757 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 438-participant average among 6 other Papillary Thyroid Cancer trials with a reported enrollment target (89% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Papillary Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Questionnaire is the first listed.
NCT07140757 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07140757 about?
NCT07140757 is a clinical study titled "Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers". To track the outcomes of patients who have been treated with RFA and its long-term effectiveness, and to learn more about the quality of life of patients who have received RFA in this study.
What is the current status of trial NCT07140757?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2025-08-18. Estimated completion is 2030-12-31.
What conditions does trial NCT07140757 study?
This clinical trial studies the following conditions: Papillary Thyroid Cancer, Radiofrequency Ablation, Low Risk.
What interventions are being tested in trial NCT07140757?
The interventions under investigation include: Questionnaire (OTHER).
Who is sponsoring clinical trial NCT07140757?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07140757 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papillary Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
RECRUITING · Phase 2
-
Targeted Therapy to Increase RAI Uptake in Metastatic DTC
RECRUITING
-
Studies on Tumors of the Thyroid
RECRUITING
-
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
ACTIVE NOT RECRUITING · Phase 1
-
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Radiofrequency Ablation of Papillary Thyroid Microcarcinoma
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.